hmmm so MRM is up 10% on what was effectively a ~30% upgrade to consensus ebitda targets. We have the usual short sighted fundies using the liquidity to lighten their positions.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress